EPIGENOMICS AG (ECX.DE) Fundamental Analysis & Valuation

FRA:ECX • DE000A37FT41

0.7 EUR
-0.09 (-11.17%)
Last: Jun 27, 2024, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This ECX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

ECX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. Both the profitability and financial health of ECX have multiple concerns. ECX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. ECX.DE Profitability Analysis

1.1 Basic Checks

  • ECX had negative earnings in the past year.
  • In the past year ECX has reported a negative cash flow from operations.
ECX.DE Yearly Net Income VS EBIT VS OCF VS FCFECX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -386.29%, ECX is doing worse than 92.00% of the companies in the same industry.
  • ECX has a Return On Equity of -853.33%. This is in the lower half of the industry: ECX underperforms 73.33% of its industry peers.
Industry RankSector Rank
ROA -386.29%
ROE -853.33%
ROIC N/A
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
ECX.DE Yearly ROA, ROE, ROICECX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

  • ECX has a better Gross Margin (76.56%) than 78.67% of its industry peers.
  • ECX's Gross Margin has declined in the last couple of years.
  • ECX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
ECX.DE Yearly Profit, Operating, Gross MarginsECX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ECX.DE Health Analysis

2.1 Basic Checks

  • ECX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ECX has more shares outstanding than it did 1 year ago.
  • ECX has a worse debt/assets ratio than last year.
ECX.DE Yearly Shares OutstandingECX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
ECX.DE Yearly Total Debt VS Total AssetsECX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

  • ECX has an Altman-Z score of -44.22. This is a bad value and indicates that ECX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -44.22, ECX is not doing good in the industry: 93.33% of the companies in the same industry are doing better.
  • ECX has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • ECX's Debt to Equity ratio of 0.06 is fine compared to the rest of the industry. ECX outperforms 73.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -44.22
ROIC/WACCN/A
WACC3.9%
ECX.DE Yearly LT Debt VS Equity VS FCFECX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

  • ECX has a Current Ratio of 1.93. This is a normal value and indicates that ECX is financially healthy and should not expect problems in meeting its short term obligations.
  • ECX's Current ratio of 1.93 is in line compared to the rest of the industry. ECX outperforms 48.00% of its industry peers.
  • ECX has a Quick Ratio of 1.93. This is a normal value and indicates that ECX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.93, ECX is in line with its industry, outperforming 50.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
ECX.DE Yearly Current Assets VS Current LiabilitesECX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ECX.DE Growth Analysis

3.1 Past

  • ECX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -7359.64%.
  • ECX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.80%.
  • Measured over the past years, ECX shows a very negative growth in Revenue. The Revenue has been decreasing by -23.61% on average per year.
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%

3.2 Future

  • ECX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.
  • Based on estimates for the next years, ECX will show a very strong growth in Revenue. The Revenue will grow by 108.06% on average per year.
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ECX.DE Yearly Revenue VS EstimatesECX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 20M 40M 60M
ECX.DE Yearly EPS VS EstimatesECX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. ECX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • ECX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ECX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ECX.DE Price Earnings VS Forward Price EarningsECX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ECX.DE Per share dataECX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ECX's earnings are expected to grow with 25.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.12%
EPS Next 3Y25.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ECX.DE Dividend Analysis

5.1 Amount

  • No dividends for ECX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ECX.DE Fundamentals: All Metrics, Ratios and Statistics

EPIGENOMICS AG

FRA:ECX (6/27/2024, 7:00:00 PM)

0.7

-0.09 (-11.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-27
Earnings (Next)09-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.90K
Revenue(TTM)448.00K
Net Income(TTM)-16.29M
Analysts80
Price Target16.32 (2231.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA N/A
EPS(TTM)-17.68
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-397.44
FCFYN/A
OCF(TTM)-367.27
OCFYN/A
SpS13.12
BVpS55.92
TBVpS54.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -386.29%
ROE -853.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.56%
FCFM N/A
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.27%
Cap/Sales 229.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -44.22
F-Score3
WACC3.9%
ROIC/WACCN/A
Cap/Depr(3y)64.84%
Cap/Depr(5y)50.54%
Cap/Sales(3y)94.83%
Cap/Sales(5y)60.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%
EBIT growth 1Y-157.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.62%
EBIT Next 3Y25.99%
EBIT Next 5Y-7.05%
FCF growth 1Y-63.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.5%
OCF growth 3YN/A
OCF growth 5YN/A

EPIGENOMICS AG / ECX.DE FAQ

What is the ChartMill fundamental rating of EPIGENOMICS AG (ECX.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ECX.DE.


What is the valuation status for ECX stock?

ChartMill assigns a valuation rating of 1 / 10 to EPIGENOMICS AG (ECX.DE). This can be considered as Overvalued.


Can you provide the profitability details for EPIGENOMICS AG?

EPIGENOMICS AG (ECX.DE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ECX stock?

The Earnings per Share (EPS) of EPIGENOMICS AG (ECX.DE) is expected to grow by 47.75% in the next year.